Loading...

BCTX BRIACELL THERAPEUTICS CORP Company Mergers 8-K Filing

BRCL

BCTX

BRIACELL THERAPEUTICS CORP

(BCTX)

2026 8-K

Financial Disclosure

Shareholder Meeting Results

Asset Acquisition

Capital Raising

Financial Update

Financial Report Filed

Share Consolidation

Equity Offerings

Financial Statements

Equity Offerings

Financial Filing

Nasdaq Compliance

Annual Meeting Results

Share Consolidation

Meeting Reschedule

Share Consolidation

Financial Filing

Public Offering

Director Resignation

Financial Disclosure

Clinical Trial Success

Positive Announcements

Financial Statements

Securities Purchase Agreements

Financial Statements

Annual General Meeting of S...

Financial Statements

Announcement of Phase 2 Stu...

Financial Statements and Ex...

Spin-out Transaction

Spin-out Transaction

Shareholder Meeting Results

FDA Approval for Bria-IMTTM...

Spin-off Agreement

Equity Issuance

Agreement and Stock Purchase

Clinical Data Presentation

Reorganization Plan

Promising Survival Data fro...

Amendment and Shareholder M...

Regulation FD Disclosure

Investigation Announcement

FDA Meeting Feedback

Patent Issuance and FDA Gui...

External Links:

On February 18, 2026, BriaCell Therapeutics Corp. announced an agreement for its subsidiary BriaPro to acquire its exclusive license for Soluble CD80 in cancer treatment, resulting in BriaCell owning approximately 78% of BriaPro after receiving 23,972,589 shares and a potential $3.0 million credit facility.

AI Assistant

BRIACELL THERAPEUTICS CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.